March 22, 2017 / 8:28 PM / 7 months ago

BRIEF-Ultragenyx seizure drug fails mid-stage study

March 22 (Reuters) - Ultragenyx Pharmaceutical Inc -

* Ultragenyx announces topline data from phase 2 UX007 glucose transporter type-1 deficiency syndrome seizure study

* Study did not meet primary endpoint

* Patients treated with UX007 demonstrated a reduction of 13.4% in overall seizure frequency relative to placebo

* There was no difference in cognitive function as assessed by cantab in patients treated with UX007 compared to placebo

* Two of 36 enrolled patients discontinued treatment during eight-week placebo-controlled period

* 12 patients have discontinued treatment during extension period to date

* Two patients discontinued due to adverse events, 4 patients due to tolerability reasons, and 8 due to compliance or study burden issues

* Ultragenyx Pharmaceutical Inc - “Look forward to studying UX007 in our phase 3 study in Glut1 DS patients with movement disorders”

* Ultragenyx Pharmaceutical Inc - “Continue to evaluate our plans in seizure indication” Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below